Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 89 entries
Sorted by: Best Match Show Resources per page
[Depression of the ST segment in the precordial leads in acute inferior myocardial infarct].

Minerva cardioangiologica

Fiorilli R, Lisanti P, Caiazza M, Zarrillo A.
PMID: 3561803
Minerva Cardioangiol. 1987 Jan-Feb;35(1):1-6.

No abstract available.

Cite
Fiorilli R, Lisanti P, Caiazza M, et al. Sottoslivellamento del tratto ST nelle derivazioni precordiali in corso di infarto acuto del miocardio in sede inferiore. [Depression of the ST segment in the precordial leads in acute inferior myocardial infarct]. Minerva Cardioangiol. 1987;35(1):1-6
Fiorilli, R., Lisanti, P., Caiazza, M., & Zarrillo, A. (1987). Sottoslivellamento del tratto ST nelle derivazioni precordiali in corso di infarto acuto del miocardio in sede inferiore. [Depression of the ST segment in the precordial leads in acute inferior myocardial infarct]. Minerva cardioangiologica, 35(1), 1-6.
Fiorilli, R, et al. "Sottoslivellamento del tratto ST nelle derivazioni precordiali in corso di infarto acuto del miocardio in sede inferiore." [Depression of the ST segment in the precordial leads in acute inferior myocardial infarct]. Minerva cardioangiologica vol. 35,1 (1987): 1-6.
Fiorilli R, Lisanti P, Caiazza M, Zarrillo A. Sottoslivellamento del tratto ST nelle derivazioni precordiali in corso di infarto acuto del miocardio in sede inferiore. [Depression of the ST segment in the precordial leads in acute inferior myocardial infarct]. Minerva Cardioangiol. 1987 Jan-Feb;35(1):1-6. Italian. PMID: 3561803.
Copy Download .nbib Format: NLM
Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics.

Oncotarget

Sotgia F, Fiorillo M, Lisanti MP.
PMID: 28978152
Oncotarget. 2017 Jul 27;8(40):68730-68745. doi: 10.18632/oncotarget.19612. eCollection 2017 Sep 15.

Here, we used a data-mining and informatics approach to discover new biomarkers of resistance to hormonal therapy in breast cancer. More specifically, we investigated whether nuclear-encoded genes associated with mitochondrial biogenesis can be used to predict tumor recurrence, distant...

Cite
Sotgia F, Fiorillo M, Lisanti MP. Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics. Oncotarget. 2017;8(40):68730-68745doi: 10.18632/oncotarget.19612.
Sotgia, F., Fiorillo, M., & Lisanti, M. P. (2017). Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics. Oncotarget, 8(40), 68730-68745. https://doi.org/10.18632/oncotarget.19612
Sotgia, Federica, et al. "Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics." Oncotarget vol. 8,40 (2017): 68730-68745. doi: https://doi.org/10.18632/oncotarget.19612
Sotgia F, Fiorillo M, Lisanti MP. Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics. Oncotarget. 2017 Jul 27;8(40):68730-68745. doi: 10.18632/oncotarget.19612. eCollection 2017 Sep 15. PMID: 28978152; PMCID: PMC5620292.
Copy Download .nbib Format: NLM
Doxycycline and therapeutic targeting of the DNA damage response in cancer cells: old drug, new purpose.

Oncoscience

Peiris-Pagès M, Sotgia F, Lisanti MP.
PMID: 26425660
Oncoscience. 2015 Aug 24;2(8):696-9. doi: 10.18632/oncoscience.215. eCollection 2015.

There is a small proportion of cells within a tumour with self-renewing properties, which is resistant to conventional therapy, and is responsible for tumour initiation, maintenance and metastasis. These cells are known as cancer stem cells (CSCs) or tumour-initiating...

Cite
Peiris-Pagès M, Sotgia F, Lisanti MP. Doxycycline and therapeutic targeting of the DNA damage response in cancer cells: old drug, new purpose. Oncoscience. 2015;2(8):696-9doi: 10.18632/oncoscience.215.
Peiris-Pagès, M., Sotgia, F., & Lisanti, M. P. (2015). Doxycycline and therapeutic targeting of the DNA damage response in cancer cells: old drug, new purpose. Oncoscience, 2(8), 696-9. https://doi.org/10.18632/oncoscience.215
Peiris-Pagès, Maria, et al. "Doxycycline and therapeutic targeting of the DNA damage response in cancer cells: old drug, new purpose." Oncoscience vol. 2,8 (2015): 696-9. doi: https://doi.org/10.18632/oncoscience.215
Peiris-Pagès M, Sotgia F, Lisanti MP. Doxycycline and therapeutic targeting of the DNA damage response in cancer cells: old drug, new purpose. Oncoscience. 2015 Aug 24;2(8):696-9. doi: 10.18632/oncoscience.215. eCollection 2015. PMID: 26425660; PMCID: PMC4580062.
Copy Download .nbib Format: NLM
Postoperative Spine Infections.

Orthopedic reviews

Parchi PD, Evangelisti G, Andreani L, Girardi F, Darren L, Sama A, Lisanti M.
PMID: 26605028
Orthop Rev (Pavia). 2015 Sep 28;7(3):5900. doi: 10.4081/or.2015.5900. eCollection 2015 Sep 28.

Postoperative spinal wound infection is a potentially devastating complication after operative spinal procedures. Despite the utilization of perioperative prophylactic antibiotics in recent years and improvements in surgical technique and postoperative care, wound infection continues to compromise patients' outcome after...

Cite
Parchi PD, Evangelisti G, Andreani L, et al. Postoperative Spine Infections. Orthop Rev (Pavia). 2015;7(3):5900doi: 10.4081/or.2015.5900.
Parchi, P. D., Evangelisti, G., Andreani, L., Girardi, F., Darren, L., Sama, A., & Lisanti, M. (2015). Postoperative Spine Infections. Orthopedic reviews, 7(3), 5900. https://doi.org/10.4081/or.2015.5900
Parchi, Paolo Domenico, et al. "Postoperative Spine Infections." Orthopedic reviews vol. 7,3 (2015): 5900. doi: https://doi.org/10.4081/or.2015.5900
Parchi PD, Evangelisti G, Andreani L, Girardi F, Darren L, Sama A, Lisanti M. Postoperative Spine Infections. Orthop Rev (Pavia). 2015 Sep 28;7(3):5900. doi: 10.4081/or.2015.5900. eCollection 2015 Sep 28. PMID: 26605028; PMCID: PMC4592931.
Copy Download .nbib Format: NLM
Corrigendum: Landscape of the mitochondrial Hsp90 metabolome in tumours.

Nature communications

Chae YC, Angelin A, Lisanti S, Kossenkov AV, Speicher KD, Wang H, Powers JF, Tischler AS, Pacak K, Fliedner S, Michalek RD, Karoly ED, Wallace DC, Languino LR, Speicher DW, Altieri DC.
PMID: 26085380
Nat Commun. 2015 Jun 18;6:7605. doi: 10.1038/ncomms8605.

No abstract available.

Cite
Chae YC, Angelin A, Lisanti S, et al. Corrigendum: Landscape of the mitochondrial Hsp90 metabolome in tumours. Nat Commun. 2015;6:7605doi: 10.1038/ncomms8605.
Chae, Y. C., Angelin, A., Lisanti, S., Kossenkov, A. V., Speicher, K. D., Wang, H., Powers, J. F., Tischler, A. S., Pacak, K., Fliedner, S., Michalek, R. D., Karoly, E. D., Wallace, D. C., Languino, L. R., Speicher, D. W., & Altieri, D. C. (2015). Corrigendum: Landscape of the mitochondrial Hsp90 metabolome in tumours. Nature communications, 67605. https://doi.org/10.1038/ncomms8605
Chae, Young Chan, et al. "Corrigendum: Landscape of the mitochondrial Hsp90 metabolome in tumours." Nature communications vol. 6 (2015): 7605. doi: https://doi.org/10.1038/ncomms8605
Chae YC, Angelin A, Lisanti S, Kossenkov AV, Speicher KD, Wang H, Powers JF, Tischler AS, Pacak K, Fliedner S, Michalek RD, Karoly ED, Wallace DC, Languino LR, Speicher DW, Altieri DC. Corrigendum: Landscape of the mitochondrial Hsp90 metabolome in tumours. Nat Commun. 2015 Jun 18;6:7605. doi: 10.1038/ncomms8605. PMID: 26085380; PMCID: PMC4750482.
Copy Download .nbib Format: NLM
Observation of the skin-depth effect on the Casimir force between metallic surfaces.

Proceedings of the National Academy of Sciences of the United States of America

Lisanti M, Iannuzzi D, Capasso F.
PMID: 16091459
Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):11989-92. doi: 10.1073/pnas.0505614102. Epub 2005 Aug 09.

We have performed measurements of the Casimir force between a metallic plate and a transparent sphere coated with metallic films of different thicknesses. We have observed that, if the thickness of the coating is less than the skin-depth of...

Cite
Lisanti M, Iannuzzi D, Capasso F. Observation of the skin-depth effect on the Casimir force between metallic surfaces. Proc Natl Acad Sci U S A. 2005;102(34):11989-92doi: 10.1073/pnas.0505614102.
Lisanti, M., Iannuzzi, D., & Capasso, F. (2005). Observation of the skin-depth effect on the Casimir force between metallic surfaces. Proceedings of the National Academy of Sciences of the United States of America, 102(34), 11989-92. https://doi.org/10.1073/pnas.0505614102
Lisanti, Mariangela, et al. "Observation of the skin-depth effect on the Casimir force between metallic surfaces." Proceedings of the National Academy of Sciences of the United States of America vol. 102,34 (2005): 11989-92. doi: https://doi.org/10.1073/pnas.0505614102
Lisanti M, Iannuzzi D, Capasso F. Observation of the skin-depth effect on the Casimir force between metallic surfaces. Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):11989-92. doi: 10.1073/pnas.0505614102. Epub 2005 Aug 09. PMID: 16091459; PMCID: PMC1189346.
Copy Download .nbib Format: NLM
Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach.

Annals of translational medicine

Cortiula F, De Maglio G, Cangi MG, Gerratana L, Lisanti C, Bonura S, Fasola G, Follador A.
PMID: 30788361
Ann Transl Med. 2019 Jan;7(1):14. doi: 10.21037/atm.2018.12.42.

We reported the case of a male patient suffering from a metastatic squamous cell carcinoma, harboring a complex inframe deletion in exon 19 of epidermal growth factor receptor (EGFR), treated with erlotinib and osimertinib and subsequently with immunotherapy. A...

Cite
Cortiula F, De Maglio G, Cangi MG, et al. Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach. Ann Transl Med. 2019;7(1):14doi: 10.21037/atm.2018.12.42.
Cortiula, F., De Maglio, G., Cangi, M. G., Gerratana, L., Lisanti, C., Bonura, S., Fasola, G., & Follador, A. (2019). Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach. Annals of translational medicine, 7(1), 14. https://doi.org/10.21037/atm.2018.12.42
Cortiula, Francesco, et al. "Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach." Annals of translational medicine vol. 7,1 (2019): 14. doi: https://doi.org/10.21037/atm.2018.12.42
Cortiula F, De Maglio G, Cangi MG, Gerratana L, Lisanti C, Bonura S, Fasola G, Follador A. Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach. Ann Transl Med. 2019 Jan;7(1):14. doi: 10.21037/atm.2018.12.42. PMID: 30788361; PMCID: PMC6351371.
Copy Download .nbib Format: NLM
"Energetic" Cancer Stem Cells (e-CSCs): A New Hyper-Metabolic and Proliferative Tumor Cell Phenotype, Driven by Mitochondrial Energy.

Frontiers in oncology

Fiorillo M, Sotgia F, Lisanti MP.
PMID: 30805301
Front Oncol. 2019 Feb 05;8:677. doi: 10.3389/fonc.2018.00677. eCollection 2018.

Here, we provide the necessary evidence that mitochondrial metabolism drives the anchorage-independent proliferation of CSCs. Two human breast cancer cell lines, MCF7 [ER(+)] and MDA-MB-468 (triple-negative), were used as model systems. To directly address the issue of metabolic heterogeneity...

Cite
Fiorillo M, Sotgia F, Lisanti MP. "Energetic" Cancer Stem Cells (e-CSCs): A New Hyper-Metabolic and Proliferative Tumor Cell Phenotype, Driven by Mitochondrial Energy. Front Oncol. 2019;8:677doi: 10.3389/fonc.2018.00677.
Fiorillo, M., Sotgia, F., & Lisanti, M. P. (2018). "Energetic" Cancer Stem Cells (e-CSCs): A New Hyper-Metabolic and Proliferative Tumor Cell Phenotype, Driven by Mitochondrial Energy. Frontiers in oncology, 8677. https://doi.org/10.3389/fonc.2018.00677
Fiorillo, Marco, et al. ""Energetic" Cancer Stem Cells (e-CSCs): A New Hyper-Metabolic and Proliferative Tumor Cell Phenotype, Driven by Mitochondrial Energy." Frontiers in oncology vol. 8 (2018): 677. doi: https://doi.org/10.3389/fonc.2018.00677
Fiorillo M, Sotgia F, Lisanti MP. "Energetic" Cancer Stem Cells (e-CSCs): A New Hyper-Metabolic and Proliferative Tumor Cell Phenotype, Driven by Mitochondrial Energy. Front Oncol. 2019 Feb 05;8:677. doi: 10.3389/fonc.2018.00677. eCollection 2018. PMID: 30805301; PMCID: PMC6370664.
Copy Download .nbib Format: NLM
Purification and molecular characterization of NP185, a neuronal-specific and synapse-enriched clathrin assembly polypeptide.

Bioquimica y patologia clinica : ByPC : revista de la Asociacion Bioquimica Argentina

Li S, Lisanti M, Puszkin S.
PMID: 31402847
Bioquim Patol Clin. 1998;62(1):5-17.

NP185, a neuronal-specific protein of 185 kDa, was first discovered when we prepared monoclonal anti-bodies (mAbs) against bovine brain clathrin coated vesicles. Two mAbs, 8G8 and 6G7, permitted us to characterize this protein both biochemically and in development (NP185...

Cite
Li S, Lisanti M, Puszkin S. Purification and molecular characterization of NP185, a neuronal-specific and synapse-enriched clathrin assembly polypeptide. Bioquim Patol Clin. 1998;62(1):5-17
Li, S., Lisanti, M., & Puszkin, S. (1998). Purification and molecular characterization of NP185, a neuronal-specific and synapse-enriched clathrin assembly polypeptide. Bioquimica y patologia clinica : ByPC : revista de la Asociacion Bioquimica Argentina, 62(1), 5-17.
Li, Shengwen, et al. "Purification and molecular characterization of NP185, a neuronal-specific and synapse-enriched clathrin assembly polypeptide." Bioquimica y patologia clinica : ByPC : revista de la Asociacion Bioquimica Argentina vol. 62,1 (1998): 5-17.
Li S, Lisanti M, Puszkin S. Purification and molecular characterization of NP185, a neuronal-specific and synapse-enriched clathrin assembly polypeptide. Bioquim Patol Clin. 1998;62(1):5-17. PMID: 31402847; PMCID: PMC6688760.
Copy Download .nbib Format: NLM
Profunda Femoris Artery Pseudoaneurysm after Intramedullary Fixation for a Pertrochanteric Hip Fracture.

Journal of orthopaedic case reports

Piolanti N, Giuntoli M, Nucci AM, Battistini P, Lisanti M, Andreani L.
PMID: 28819608
J Orthop Case Rep. 2017 Mar-Apr;7(2):74-77. doi: 10.13107/jocr.2250-0685.758.

INTRODUCTION: Vascular complications after femoral fixation are rare and not only easy to recognize but also potentially life-threatening. The aim of this case report is to describe how a pseudoaneurysm of the deep femoral artery can complicate an intramedullary...

Cite
Piolanti N, Giuntoli M, Nucci AM, et al. Profunda Femoris Artery Pseudoaneurysm after Intramedullary Fixation for a Pertrochanteric Hip Fracture. J Orthop Case Rep. 2017;7(2):74-77doi: 10.13107/jocr.2250-0685.758.
Piolanti, N., Giuntoli, M., Nucci, A. M., Battistini, P., Lisanti, M., & Andreani, L. (2017). Profunda Femoris Artery Pseudoaneurysm after Intramedullary Fixation for a Pertrochanteric Hip Fracture. Journal of orthopaedic case reports, 7(2), 74-77. https://doi.org/10.13107/jocr.2250-0685.758
Piolanti, Nicola, et al. "Profunda Femoris Artery Pseudoaneurysm after Intramedullary Fixation for a Pertrochanteric Hip Fracture." Journal of orthopaedic case reports vol. 7,2 (2017): 74-77. doi: https://doi.org/10.13107/jocr.2250-0685.758
Piolanti N, Giuntoli M, Nucci AM, Battistini P, Lisanti M, Andreani L. Profunda Femoris Artery Pseudoaneurysm after Intramedullary Fixation for a Pertrochanteric Hip Fracture. J Orthop Case Rep. 2017 Mar-Apr;7(2):74-77. doi: 10.13107/jocr.2250-0685.758. PMID: 28819608; PMCID: PMC5553843.
Copy Download .nbib Format: NLM
Search for Dark Matter Annihilation in Galaxy Groups.

Physical review letters

Lisanti M, Mishra-Sharma S, Rodd NL, Safdi BR.
PMID: 29570342
Phys Rev Lett. 2018 Mar 09;120(10):101101. doi: 10.1103/PhysRevLett.120.101101.

We use 413 weeks of publicly available Fermi Pass 8 gamma-ray data combined with recently developed galaxy group catalogs to search for evidence of dark matter annihilation in extragalactic halos. In our study, we use luminosity-based mass estimates and...

Cite
Lisanti M, Mishra-Sharma S, Rodd NL, et al. Search for Dark Matter Annihilation in Galaxy Groups. Phys Rev Lett. 2018;120(10):101101doi: 10.1103/PhysRevLett.120.101101.
Lisanti, M., Mishra-Sharma, S., Rodd, N. L., & Safdi, B. R. (2018). Search for Dark Matter Annihilation in Galaxy Groups. Physical review letters, 120(10), 101101. https://doi.org/10.1103/PhysRevLett.120.101101
Lisanti, Mariangela, et al. "Search for Dark Matter Annihilation in Galaxy Groups." Physical review letters vol. 120,10 (2018): 101101. doi: https://doi.org/10.1103/PhysRevLett.120.101101
Lisanti M, Mishra-Sharma S, Rodd NL, Safdi BR. Search for Dark Matter Annihilation in Galaxy Groups. Phys Rev Lett. 2018 Mar 09;120(10):101101. doi: 10.1103/PhysRevLett.120.101101. PMID: 29570342.
Copy Download .nbib Format: NLM
Doxycycline, an Inhibitor of Mitochondrial Biogenesis, Effectively Reduces Cancer Stem Cells (CSCs) in Early Breast Cancer Patients: A Clinical Pilot Study.

Frontiers in oncology

Scatena C, Roncella M, Di Paolo A, Aretini P, Menicagli M, Fanelli G, Marini C, Mazzanti CM, Ghilli M, Sotgia F, Lisanti MP, Naccarato AG.
PMID: 30364293
Front Oncol. 2018 Oct 12;8:452. doi: 10.3389/fonc.2018.00452. eCollection 2018.

No abstract available.

Cite
Scatena C, Roncella M, Di Paolo A, et al. Doxycycline, an Inhibitor of Mitochondrial Biogenesis, Effectively Reduces Cancer Stem Cells (CSCs) in Early Breast Cancer Patients: A Clinical Pilot Study. Front Oncol. 2018;8:452doi: 10.3389/fonc.2018.00452.
Scatena, C., Roncella, M., Di Paolo, A., Aretini, P., Menicagli, M., Fanelli, G., Marini, C., Mazzanti, C. M., Ghilli, M., Sotgia, F., Lisanti, M. P., & Naccarato, A. G. (2018). Doxycycline, an Inhibitor of Mitochondrial Biogenesis, Effectively Reduces Cancer Stem Cells (CSCs) in Early Breast Cancer Patients: A Clinical Pilot Study. Frontiers in oncology, 8452. https://doi.org/10.3389/fonc.2018.00452
Scatena, Cristian, et al. "Doxycycline, an Inhibitor of Mitochondrial Biogenesis, Effectively Reduces Cancer Stem Cells (CSCs) in Early Breast Cancer Patients: A Clinical Pilot Study." Frontiers in oncology vol. 8 (2018): 452. doi: https://doi.org/10.3389/fonc.2018.00452
Scatena C, Roncella M, Di Paolo A, Aretini P, Menicagli M, Fanelli G, Marini C, Mazzanti CM, Ghilli M, Sotgia F, Lisanti MP, Naccarato AG. Doxycycline, an Inhibitor of Mitochondrial Biogenesis, Effectively Reduces Cancer Stem Cells (CSCs) in Early Breast Cancer Patients: A Clinical Pilot Study. Front Oncol. 2018 Oct 12;8:452. doi: 10.3389/fonc.2018.00452. eCollection 2018. PMID: 30364293; PMCID: PMC6194352.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 89 entries